Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19672501 | 1.00 | BRD4 (0.40) | BRD4HCAR3BACE1BACE2HDAC1 | |
| SCHEMBL19672457 | 0.87 | BRD4 (0.39) | BRD4HCAR3HDAC1 | |
| SCHEMBL16703654 | 0.87 | BRD4 (0.39) | BRD4HCAR3HDAC1 | |
| SCHEMBL22969294 | 0.82 | HCAR3 (0.47) | BRD4HCAR3 | |
| SCHEMBL19672467 | 0.77 | BRD4 (0.40) | BRD4HCAR3 | |
| SCHEMBL20105148 | 0.77 | SLC6A4 (0.39) | SLC6A4SLC6A2 | |
| SCHEMBL17254682 | 0.77 | SLC6A4 (0.39) | SLC6A4SLC6A2 | |
| SCHEMBL16707133 | 0.77 | BRD4 (0.40) | BRD4HCAR3 | |
| SCHEMBL4508323 | 0.77 | MARK3 (0.35) | BRD4SLC6A4SLC6A2 | |
| SCHEMBL2488278 | 0.68 | TDP1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| WO-2019145410-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| EP-3140304-B1 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3066104-B1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-12-06 | — | — | EP | disclosed |
| US-9428513-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428513-B2 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428515-B2 | Benzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428515-B2 | Benzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-20150322073-A1 | Benzimidazole Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| US-20150322073-A1 | Benzimidazole Derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| WO-2015169962-A1 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015067770-A1 | TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133447-A1 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-20150133447-A1 | Triazolopyrazine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038602-A1 | COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA | BRD4, MCL1, BET1 | BRD4 1/4885HCAR3 1489/4885BACE1 4783/4885 |
| US-20150133447-A1 | Triazolopyrazine | MKI67, TPX2, CCND3 | BRD4 1706/4885HCAR3 1037/4885BACE1 4184/4885 |
| US-20150322073-A1 | Benzimidazole Derivatives | MKI67, CCNI, CCND1 | BRD4 78/4885HCAR3 3403/4885BACE1 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.